옵션 체인은 다양한 행사가격과 만기일에 대한 Peakstone Realty Tr의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Peakstone Realty Tr에 대한 시장 심리를 평가합니다..

Peakstone Realty Tr (NYSE:PKST) 주식, 옵션 체인

Peakstone Realty Tr

Peakstone Realty Trust is an internally managed, publicly registered real estate investment trust (REIT) that owns and operates predominately single-tenant industrial and office properties with creditworthy tenants and long-term leases. Peakstone's portfolio consists of newer vintage, and well-located real estate assets in majorly high-growth coastal and sunbelt markets. The company has two reportable segments: Industrial and Office. The Industrial segment consists of industrial outdoor storage properties which have a low building-to-land ratio, or low coverage, maximizing yard space for the display, movement, and storage of materials and equipment. The Office segment includes office, R&D and data center properties.

Peakstone Realty Trust

Stephens &amp; Co. analyst Russell Gunther reiterates Amerant Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTB#NYSE">AMTB</a>) with a Overweight and maintains $24 price target.

News

Price Target

Reiteration

Analyst Ratings

AMTB

Stephens & Co. Reiterates Overweight on Amerant Bancorp, Maintains $24 Price Target

Raymond James analyst Alexander Sklar maintains Weave Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEAV#NYSE">WEAV</a>) with a Strong Buy and lowers the price target from $20 to $17.

WEAV

Raymond James Maintains Strong Buy on Weave Communications, Lowers Price Target to $17

FOXO Technologies Inc. (NYSE:<a href="https://www.benzinga.com/stock/FOXO#NYSE">FOXO</a>)&nbsp;("FOXO" or the "Company"), today announced that effective 4.01pm Eastern Time, on April 28, 2025, (the "Effective Time"), the Company completed a 1 for 10 reverse stock split of its outstanding common stock. The Company's common stock will open for trading on Tuesday April 29, 2025, on a post-split basis and continue to trade under the symbol FOXO.
As a result of the reverse split, every 10 shares of the Company's common stock issued and outstanding on the Effective Time will be consolidated into one issued and outstanding share with no change in the nominal par value per share of $0.0001. No fractional shares will be outstanding following the Reverse Stock Split. Holders of fractional shares will be entitled to receive, in lieu of any fractional share, the number of shares rounded up to the next whole number.
Based on the number of shares outstanding on April 28, 2025, the reverse stock will reduce the number of shares of the Company's common stock from approximately 38.7 million pre-reverse split shares to approximately 3.87 million post-reverse-split.

FOXO

FOXO Technologies Completes 1 For 10 Reverse Stock Split Of Outstanding Common Stock

Raymond James analyst Alexander Sklar maintains PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) with a Outperform and lowers the price target from $10 to $8.

AIOT

Raymond James Maintains Outperform on PowerFleet, Lowers Price Target to $8

President Donald Trump has now been back in the White House for 100 days, with Tuesday marking the 100th day of his second term, following his inauguration on <a href="https://www.benzinga.com/general/entertainment/25/01/43139381/how-many-people-watched-donald-trumps-2025-inauguration-spoiler-less-than-biden-four-years-ago" target="_blank" rel="noopener">January 20, 2025</a><a href="https://www.benzinga.com/general/entertainment/25/01/43139381/how-many-people-watched-donald-trumps-2025-inauguration-spoiler-less-than-biden-four-years-ago">.</a>
Here's a look at where Trump stands with his election promises, voter polls, signing of laws and executive orders and the stock market after his first 100 days.
Promises Made, Promises Kept?: Ahead of the<a href="https://www.benzinga.com/government/regulations/25/01/43085323/trump-sworn-in-as-47th-president-declares-golden-age-of-america-begins-right-now"> 2024 presidential election</a>, Trump made numerous campaign promises, including some that he said he would ensure were completed within his first 100 days.
Here were some of the larger campaign issues and where Trump stands today.
<ul>
<li>Immigration: still in progress, but has mostly done what he said he would do.</li>
<li>Bring down prices: mixed with gas and energy prices down, but the cost of groceries now rising related to tariffs.</li>
<li>Tariffs: Trump said he would deploy tariffs, and that's what he has done, with a 10% tariff on all imports and higher reciprocal tariffs on many countries. While the tariffs have been paused or changed multiple times, Trump's promise of tariffs came true.</li>
<li>Ukraine-Russia War: Trump promised to end the war in Ukraine on his first day in office, but that is far from being true. Still a work in progress, with Trump meeting with Ukrainian President Volodymyr Zelenskyy and talking to Russian President Vladimir Putin.</li>
<li>Men in Women's Sports: Trump promised to change rules for transgenders to keep men out of women's sports and this one he's done or is working on with an executive order signed to ban men from competing in women's sports.</li>
<li>Others: While the above were the larger campaign promises, Trump has also pardoned over 1,500 people, including those involved in the Jan. 6 attack on the U.S. Capitol, which was an election promise. Trump has also worked to end DEI initiatives in the U.S. government and had the Department of Government Efficiency focus on making job cuts and eliminating programs to achieve cost savings. Other promises of tax cuts, including no taxes on tips, no taxes on overtime pay, and no interest on car loans haven't happened yet.</li>
</ul>
A scorecard <a href="https://apnews.com/projects/trump-campaign-promise-tracker/">from </a>the Associated Press grades Trump's campaign promises as four kept, 15 in progress and five as "it's complicated. The scorecard above not counting the others category, shows two promises kept and three as in process or not done.
Read Also:<a href="https://www.benzinga.com/news/global/25/04/45047432/trump-says-i-run-the-country-and-the-world-yet-polls-plummet"> Trump Says &#8216;I Run The Country And The World,&#8217; Yet Polls Plummet</a>
Laws and Executive Orders: When it comes to signing executive orders, Trump has been busy, having signed <a href="https://www.federalregister.gov/presidential-documents/executive-orders/donald-trump/2025" target="_blank" rel="noopener">over </a>130 since becoming president. While this leads to the claim that Trump has been one of the most productive presidents in history, it's essential to understand that this is based on executive orders, not laws passed.
As reported by <a href="https://punchbowl.news/article/white-house/trump-bills-first-hundred-days/">Punchbowl</a>, Trump has signed fewer bills into law in his first 100 days than any other new president in the last 70 years. Since taking office, Trump has signed only five bills into law, with the main one being the Laken Riley Act and the others being a stopgap funding bill to avoid a government shutdown and Congressional Review Acts to overturn regulations from the previous administration.
To put the figure into perspective, the report highlights that in the first 100 days of his last presidency, Trump had signed 28 bills into law.
The White House likes to highlight the number of executive orders signed by Trump in the first day closing in on the total number signed by President Joe Biden (162) during his entire presidency, but some presidents don't sign as many executive orders and focus on signing bills into law.
Executive orders are used to tell federal agencies how to enforce laws as long as it does not violate the Constitution or any federal laws, which in some cases have already been tested by the courts.
Voter Polls: Trump won the 2024 presidential election in both the Electoral College vote (312 to 226) and the popular vote (49.8% to 48.3%). Trump also has majority control in both the House and Senate.
While Trump may have been popular with around 50% or more of voters ahead of the 2024 election, he has lost support in the first 100 days. Along with losing support and having lower favorability ratings, Trump is also losing approval in key categories like handling of the economy.
A recent Morning Consult <a href="https://pro.morningconsult.com/trackers/donald-trump-congress-policy-republicans-polling?utm_source=briefing&amp;utm_medium=email&amp;utm_campaign=washington_am&amp;utm_content=042225">poll </a>found that 49% of voters disapprove of Trump's handling of the economy, which marks his worst net approval rating in the category.
A recent New York Times/Siena College<a href="https://www.benzinga.com/news/25/04/45027947/trumps-second-term-viewed-as-chaotic-and-scary-by-majority-of-voters"> poll</a> uses words like "chaotic" and "scary" to describe Trump's first 100 days in office. In the poll 66% of voters say Trump's second term is "chaotic," while 59% say the second term is "scary."
When asked about specific issues in the poll, voters gave Trump negative ratings across all categories, with his actions on immigration getting the highest approval rating of 47%. Trump's overall approval rating in the poll was 42%.
A newer Associated Press-NORC Center for Public Affairs Research poll<a href="https://www.benzinga.com/markets/equities/25/04/45027881/trumps-approval-plummets-as-tariffs-bite-americans-expect-skyrocketing-prices-and-shrinking-wallets"> found that rising costs</a> and Trump's handling of the economy hurt his overall approval rating.
In the poll, around 60% of voters said they disapproved of Trump's handling of the economy, with nearly 75% predicting that tariffs will increase consumer prices.
Tariffs were negative in the poll, with 52% of voters saying they are against any tariffs and 59% of voters saying Trump took tariffs too far.
Trump didn't win the youth vote, but was able to take a larger percentage than Republican candidates had in recent presidential elections. Those same younger voters (aged 18 to 29) <a href="https://www.benzinga.com/news/events/25/04/44971154/trump-fails-to-impress-americas-young-shows-poll-as-they-still-favor-biden-only-15-think-us-on-right-track">are now speaking out </a>about the future of the country.
A new Harvard Youth Poll found that only 15% of young voters believe the nation is headed in the right direction. Fifty-one percent of the voters said the country is on the wrong track, with 31% currently unsure.
Trump's approval rating in the youth poll recently stood at 31%.
Stock Market Performance: The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), is down 7.8% from its closing price on January 17, when Biden was still in office, to its current price.
The ETF closed at $597.58 on Jan. 17 before opening at $600.12 on Jan. 21 with optimism from investors for Trump's next term.
The Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the Nasdaq 100, is down 9.5% over Trump's first 99 days in office. The ETF and index have fallen on tariff concerns, hurting the technology sector hard.
With Trump's first 100 days nearly complete, the president is setting new milestones, but not in a good way. &nbsp;
According to <a href="https://www.cnbc.com/2025/04/28/trumps-first-100-days-are-the-worst-for-the-stock-market-since-nixon.html">CNBC</a>, the 7.9% drop in the S&amp;P 500 through Friday was the worst start to a four-year term since Richard Nixon in 1973, citing data from CFRA Research.
In 1973, the S&amp;P 500 fell 9.9% in the first 100 days of Nixon&#8217;s presidency. For comparison, the S&amp;P 500 has an average return of 2.1% in the first 100 days of a presidency, dating back to 1944.
Also, keep in mind that recent presidents had some of the best stock market performances in their first 100 days in office. Here are the recent returns and their rating since 1944:
<ul>
<li>2009: Barack Obama, +8.4%, fourth best</li>
<li>2013: Barack Obama, +7.5%, sixth best</li>
<li>2017: Donald Trump, +5.0%, seventh best</li>
<li>2021: Joe Biden, +8.5%, third best</li>
<li>2025: Donald Trump, -7.9%, twentieth and second worst</li>
</ul>
Markets traded higher in November and December on the heels of Trump's win, with some of the largest companies in the world hitting new all-time highs. January and February also saw gains after Trump took office.
Attention shifted towards economic policies and foreign in March and April, with markets diving in April after Trump's tariff announcement.
What's Next: Trump's first 100 days represent a portion of the 1,461 days the president would have under his current term, or roughly 6.8%.
While the time marks only a small portion of Trump's term, the first 100 days are important because they often reveal what the entire four-year term could be about and how things may play out.
Industry experts <a href="https://www.franklintempleton.com/articles/2025/institute/quick-thoughts-trumps-first-100-days-economic-impact-and-market-insights">believe </a>that Trump and his administration have a "high tolerance" for market pain and are mainly focused on resetting the economy.
Trump and his team have oftentimes said there could be short-term pain in consumer prices and stock market gains, which is all a part of a plan to make Americans rich in the future.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent042825">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
Read Next:
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent042825"><img loading="lazy" decoding="async" width="1024" height="330" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28215932/Picture1-4-1024x330.png" alt="" class="wp-image-891898" style="width:920px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28215932/Picture1-4-1024x330.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28215932/Picture1-4-300x97.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28215932/Picture1-4-768x248.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28215932/Picture1-4.png 1430w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45066479/rare-bullish-signal-just-flashed-on-wall-street-will-it-power-sp-500-to-6000">Rare Bullish Signal Just Flashed On Wall Street: Will It Power S&amp;P 500 To 6,000?</a></li>
</ul>
Photo: noamgalai/Shutterstock

Broad U.S. Equity ETFs

Politics

ETFs

Trump's First 100 Days: What He Delivered, Where He Fell Short, How Markets Reacted

U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 100 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.35% to 40,369.59 while the NASDAQ fell 0.10% to 17,349.14. The S&amp;P 500 also fell, dropping, 0.03% to 5,527.22.
Check This Out: <a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a>
Leading and Lagging Sectors Real estate shares jumped by 0.6% on Monday.
In trading on Monday, energy fell by 1.2%.
Top Headline
The Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) reported better-than-expected earnings for its first quarter on Tuesday.
The company posted quarterly earnings of 73 cents per share which beat the analyst consensus estimate of 72 cents per share. The company reported quarterly sales of $11.10 billion which missed the analyst consensus estimate of $11.14 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares shot up 103% to $0.0262.</li>
<li>Shares of Damon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>)got a boost, surging 86% to $0.0070.</li>
<li>WW International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) shares were also up, gaining 62% to $0.6686 after the company announced a pharmacy integration with Eli Lilly&#8217;s LillyDirect pharmacy provider, Gifthealth.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) shares dropped 77% to $0.1388.</li>
<li>Shares of Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) were down 55% to $0.0259.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) was down, falling 28% to $0.0965.</li>
</ul>
Commodities In commodity news, oil traded down 2% to $60.79 while gold traded down 0.9% at $3,318.10.
Silver traded up 1.8% to $33.595 on Tuesday, while copper rose 0.3% to $4.9030.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 gained 0.3%, Germany's DAX 40 gained 0.6% and France's CAC 40 fell 0.3%. Spain's IBEX 35 Index fell 0.8%, while London's FTSE 100 rose 0.4%.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with China's Shanghai Composite falling 0.05%, Hong Kong's Hang Seng Index gaining 0.16% and India's BSE Sensex gaining 0.09%.
Economics
<ul>
<li>The number of job openings in the U.S. declined by 288,000 to 7.192 million in March, compared to market estimates of 7.48 million.</li>
<li>The S&amp;P CoreLogic Case-Shiller Home Price Index increased 4.5% year-over-year in February.</li>
<li>The FHFA house price index increased by 0.1% in February versus a revised 0.3% rise in January.</li>
<li>U.S. wholesale inventories climbed 0.5% month-over-month to $908 billion during March.</li>
<li>The U.S. trade deficit in goods increased to $162 billion in March compared to market estimates of a $146 billion gap.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45065334/amazon-com-to-253-here-are-10-top-analyst-forecasts-for-tuesday">Amazon.com To $253? Here Are 10 Top Analyst Forecasts For Tuesday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AGMH

IXHL

LGMK

PTPI

US Stocks Mixed; Coca-Cola Posts Upbeat Earnings

AstraZeneca Plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Tuesday reported first-quarter 2025 sales of $13.59 billion, up 7% year over year (+10% at constant currency), slightly missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $13.71 billion</a>, driven by double-digit growth in oncology and biopharmaceuticals.
The company&#8217;s adjusted EPADS&nbsp;reached&nbsp;$1.25, beating the consensus of $1.11. The adjusted EPS was $2.09 (1 ADR = 2 Common Shares).
AstraZeneca&#8217;s top business, oncology,&nbsp;<a href="https://www.astrazeneca.com/content/dam/az/PDF/2025/q1/Q1-2025-results-announcement.pdf" target="_blank" rel="noreferrer noopener">increased</a>&nbsp;10% (up 13% on constant currency) to $5.64 billion.
<ul>
<li>Tagrisso sales were up 5% to $1.68 billion (8% at CER), Imfinzi revenues were up 13% (+16%) to $1.26 billion, Calquence sales increased 6% to $762 million, Lynparza sales increased 3% (+8%) to $726 million, and Enhertu revenue was up 29% (39% at CER) to $596 million.</li>
<li>On Tuesday, The Committee for Medicinal Products for Human Use of the European Medicines Agency <a href="https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-recommended-in-eu-for-cll.html" target="_blank" rel="noreferrer noopener">recommended</a> approving a fixed-duration regimen of Calquence&nbsp;in combination with venetoclax, with or without obinutuzumab, for adult patients with previously untreated chronic lymphocytic leukemia.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
Cardiovascular, Renal, and Metabolism (CVRM) sales increased 8% (up 12% at CER) to&nbsp;$3.25 billion.
<ul>
<li>Farxiga sales were up 11% (16% at CER) to $2.06 billion.</li>
</ul>
Respiratory &amp; Immunology (R&amp;I) sales increased 11% (13% CER) to $2.08 billion.
<ul>
<li>Symbicort revenues fell 6% (-3% CER) to $723 million, and Fasenra sales increased 17% (+19%) to $418 million.</li>
</ul>
Rare Disease drug sales decreased by 3% to&nbsp;$2.04 billion.
<ul>
<li>Ultomiris sales were up 22% (25% at CER) to $1.05 billion, offset by a 40% decline in Soliris (38% at CER) to $444 million.</li>
</ul>
China: In relation to the illegal drug importation <a href="https://www.wsj.com/health/pharma/astrazeneca-sales-earnings-rise-warns-of-mounting-legal-challenges-in-china-718ddef7">allegations</a>, AstraZeneca received an Appraisal Opinion from the Shenzhen City Customs Office regarding suspected unpaid importation taxes amounting to $1.6 million, referring to the Appraisal Opinion related to Enhertu.
<ul>
<li>A fine of between one and five times (up to $8 million) the amount of unpaid importation taxes may also be levied if AstraZeneca is found liable.</li>
<li>China&#8217;s sales accounted for 13% of quarterly sales, which is up 3% on a reported basis to&nbsp;<a href="https://www.benzinga.com/general/biotech/25/02/43527514/astrazeneca-q4-earnings-revenue-and-eps-beat-on-higher-cancer-and-respiratory-drug-sales-faces-4-5-million-potential-fine-in-china" target="_blank" rel="noreferrer noopener">$1.81 billion (+5% at CER)</a>.</li>
</ul>
AstraZeneca CEO Pascal Soriot said the company is &#8220;firmly committed to investing and growing in the U.S.&#8221; and continues to benefit from a &#8220;broad-based source of revenue and global manufacturing footprint.&#8221; 
AstraZeneca has 11 production sites in the U.S. covering small molecules, biologics as well as cell therapy. It also has two large R&amp;D sites in Gaithersburg MD and Cambridge MA.&#8221;
Guidance:&nbsp;For fiscal year 2025, AstraZeneca forecasts total revenue to increase by a high single-digit percentage and core EPS to increase by a low double-digit percentage.
On Tuesday, AstraZeneca <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-capitello-280-phase-iii-trial.html" rel="noreferrer noopener">announced</a> the discontinuation of its CAPItello-280 Phase 3 trial of Truqap&nbsp;(capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared to docetaxel and ADT with placebo in patients with metastatic castration-resistant prostate cancer.
The Independent Data Monitoring Committee reviewed and concluded that the&nbsp;Truqap&nbsp;combination was unlikely to meet the dual primary endpoints of radiographic progression-free survival and overall survival versus the comparator arm upon trial completion.
Price Action:&nbsp;AZN stock is down 0.13% at $69.84 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/45051380/plaintiff-sues-eli-lilly-johnson-johnson-over-alleged-breast-cancer-risk-linked-to-antipsychotic-medications" target="_blank" rel="noreferrer noopener">Plaintiff Sues Eli Lilly, Johnson &amp; Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications</a></li>
</ul>
Image: Shutterstock

Biotech

Large Cap

Guidance

Health Care

Movers

General

AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty

New Plan Latest Addition to Company's Comprehensive Benefits, Including Minimum $20 Starting Wage, Market-Leading Retirement Contributions and Tuition-Free Education
STAMFORD, Conn., April 29, 2025 /PRNewswire/ --&nbsp;Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) today announced the launch of an Employee Stock Purchase Plan (ESPP), designed to encourage and reward employee tenure and empower its workforce to share in the Company's success. Eligible employees will now have the opportunity to purchase Charter stock through payroll deductions and will receive matching Restricted Stock Units (RSUs) based on their years with Charter.

CHTR

Charter Communications Launches ESPP, Offering Employees Stock Purchase And Tenure-Based RSUs

Raymond James analyst Patrick Tyler Brown maintains Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) with a Outperform and lowers the price target from $300 to $295.

Raymond James Maintains Outperform on Vulcan Materials, Lowers Price Target to $295

Raymond James analyst Patrick Tyler Brown maintains Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) with a Outperform and lowers the price target from $600 to $597.

Raymond James Maintains Outperform on Martin Marietta Materials, Lowers Price Target to $597

Raymond James analyst Patrick Tyler Brown maintains Construction Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROAD#NASDAQ">ROAD</a>) with a Strong Buy and lowers the price target from $104 to $100.

ROAD

Raymond James Maintains Strong Buy on Construction Partners, Lowers Price Target to $100

Kinross Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>) has outperformed the market over the past 5 years by 2.13% on an annualized basis producing an average annual return of 16.3%. Currently, Kinross Gold has a market capitalization of $17.94 billion. 
Buying $100 In KGC: If an investor had bought $100 of KGC stock 5 years ago, it would be worth $213.08 today based on a price of $14.58 for KGC at the time of writing.
<h3>Kinross Gold's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745936112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

FitVine Wine becomes official wine sponsor of Life Time Pickleball, bringing delicious zero-sugar wine to more than 775 courts across the U.S.
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fitvinewine.com%2F&amp;esheet=54245288&amp;newsitemid=20250429419535&amp;lan=en-US&amp;anchor=FitVine+Wine&amp;index=1&amp;md5=b149c0cdc8bf94d2d6c142ce9c60a8cf">FitVine Wine</a>, a leading wellness wine brand, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lifetime.life%2F&amp;esheet=54245288&amp;newsitemid=20250429419535&amp;lan=en-US&amp;anchor=Life+Time&amp;index=2&amp;md5=dec070fb7e9a8dce6810e8784a7eea26">Life Time</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>), the nation's premier healthy lifestyle brand, today announced an exciting new agreement designed to bring mindful indulgence to Life Time members nationwide. As the official wine sponsor of Life Time Pickleball, FitVine will be integrated into a variety of premium social and wellness experiences in clubs across the country, including select Life Time Pickleball Classic tournaments and Afterglo events.

Fitvine Wine And Life Time Announce New Agreement To Bring Mindful Indulgence To Life Time Members Nationwide

WIIM

RCL stock has given up its prior gain. Royal Caribbean shares were trading higher after the company raised its FY25 adjusted EPS guidance.

<ul>
<li>Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies.</li>
<li>High transgene expression and improved safety profile of Aldveron's Nanoplasmid&#x2122;&nbsp;vector technology and the gentle gene-delivery of Kytopen's Flowfect Tx&#x2122; platform with unlimited scale, together offer enhanced CRISPR-mediated T-cell engineering resulting in high yields.</li>
<li>A poster summarizing the data will be presented at ISCT, May 7-10, 2025, in New Orleans.</li>
</ul>
CAMBRIDGE, Mass. and FARGO, N.D., April 29, 2025 /PRNewswire/ --&nbsp;Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies and Aldevron, a leading global manufacturer serving organizations in the gene editing, mRNA vaccine and therapeutics, viral gene therapy, and modified gene therapy spaces; today announced,&nbsp;a joint marketing agreement aimed at enhancing the workflow solutions for cell therapy manufacturers. The collaboration will focus on the joint promotion of the synergies achieved by combining the Aldveron Nanoplasmid&#x2122; vector technology with Kytopen's Flowfect Tx&#x2122; GMP cellular engineering platform in CRISPR-mediated engineering of primary T Cells.

Kytopen And Aldevron Announce Joint Marketing Agreement To Enhance Workflow Solutions For Cell Therapy Manufacturers

Raymond James analyst Savanthi Syth reiterates Southwest Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) with a Outperform and lowers the price target from $42 to $40.

Raymond James Reiterates Outperform on Southwest Airlines, Lowers Price Target to $40

Eagle Bancorp Montana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBMT#NASDAQ">EBMT</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.32 by 28.12 percent. This is a 70.83 percent increase over earnings of $0.24 per share from the same period last year. The company reported quarterly sales of $20.92 million which beat the analyst consensus estimate of $16.64 million by 25.74 percent. This is a 37.49 percent increase over sales of $15.21 million the same period last year.

Earnings Beats

EBMT

Eagle Bancorp Montana Q1 EPS $0.41 Beats $0.32 Estimate, Sales $20.92M Beat $16.64M Estimate

Raymond James analyst Ric Prentiss reiterates SBA Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) with a Strong Buy and raises the price target from $265 to $268.

SBAC

Raymond James Reiterates Strong Buy on SBA Communications, Raises Price Target to $268

<a href="https://www.paloaltonetworks.com/content/pan/en_US/company/press/2025/at-t-joins-forces-with-palo-alto-networks-to-introduce-secure-connectivity-solution-for-business-customers.html">https://www.paloaltonetworks.com/content/pan/en_US/company/press/2025/at-t-joins-forces-with-palo-alto-networks-to-introduce-secure-connectivity-solution-for-business-customers.html</a>

PANW

AT&T Joins Forces with Palo Alto Networks to Introduce Secure Connectivity Solution for Business Customers

Raymond James analyst Andrew Cooper reiterates Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) with a Outperform and lowers the price target from $145 to $120.

Comments

Peakstone Realty Tr

Peakstone Realty Tr (PKST) 옵션

Peakstone Realty Tr (NYSE:PKST) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌